

Karen M Facey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/799493/publications.pdf>

Version: 2024-02-01

29
papers

859
citations

623734

14
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

930
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 334-340. | 0.5 | 205 |
| 2 | What principles should govern the use of managed entry agreements?. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 77-83. | 0.5 | 123 |
| 3 | Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 50. | 2.7 | 72 |
| 4 | EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment. <i>Frontiers in Medicine</i> , 2018, 5, 231. | 2.6 | 47 |
| 5 | HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. <i>Health Policy</i> , 2019, 123, 140-151. | 3.0 | 43 |
| 6 | Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU – actions for stakeholders. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 459-468. | 0.5 | 35 |
| 7 | EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 715-723. | 0.5 | 31 |
| 8 | GENERATING HEALTH TECHNOLOGY ASSESSMENT EVIDENCE FOR RARE DISEASES. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 416-422. | 0.5 | 30 |
| 9 | Virtual community consultation? Using the literature and weblogs to link community perspectives and health technology assessment. <i>Health Expectations</i> , 2008, 11, 189-200. | 2.6 | 27 |
| 10 | IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 201-206. | 0.5 | 27 |
| 11 | Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 189. | 2.7 | 26 |
| 12 | Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. <i>Pharmacoeconomics</i> , 2021, 39, 1021-1044. | 3.3 | 23 |
| 13 | The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. <i>Frontiers in Pharmacology</i> , 2021, 12, 699466. | 3.5 | 22 |
| 14 | Putting Patients at the Centre of Healthcare: Progress and Challenges for Health Technology Assessments. <i>Patient</i> , 2018, 11, 581-589. | 2.7 | 20 |
| 15 | The use of nonrandomized evidence to estimate treatment effects in health technology assessment. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1035-1043. | 1.4 | 18 |
| 16 | Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 266-272. | 0.5 | 15 |
| 17 | Patient-focused HTAs. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 273-274. | 0.5 | 14 |
| 18 | Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 869-886. | 0.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, . | 0.5 | 8 |
| 20 | As health technology assessment evolves so must its approach to patient involvement. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 549-554. | 1.4 | 7 |
| 21 | Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e65. | 0.5 | 7 |
| 22 | Developing the Mosaic of Patient Participation in HTA. , 2017, , 51-66. | | 7 |
| 23 | Consideration of quality of life in the health technology assessments of rare disease treatments. <i>European Journal of Health Economics</i> , 2022, 23, 645-669. | 2.8 | 7 |
| 24 | The Imperative for Patient-Centred Research to Develop Better Quality Services in Rare Diseases. <i>Patient</i> , 2015, 8, 1-3. | 2.7 | 5 |
| 25 | Patient Input to HTA. , 2017, , 67-79. | | 5 |
| 26 | Measuring What Matters: Little Evidence Supporting the Content Validity of EQ-5D in People with Duchenne Muscular Dystrophy and Their Caregivers. <i>Medical Decision Making</i> , 2022, 42, 139-140. | 2.4 | 5 |
| 27 | A framework for action to improve patient and public involvement in health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, . | 0.5 | 5 |
| 28 | Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1674. | 2.6 | 4 |
| 29 | Reflections for Future Development. , 2017, , 419-427. | | 3 |